United Therapeutics Corp (FRA:UTH)
€ 245.3 4.6 (1.91%) Market Cap: 10.88 Bil Enterprise Value: 8.92 Bil PE Ratio: 12.50 PB Ratio: 2.19 GF Score: 89/100

United Therapeutics Corp at Cowen HealthCare Conference Transcript

Mar 03, 2020 / 01:40PM GMT
Release Date Price: €93.5 (+2.19%)
Chris Shibutani
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

My name is Chris Shibutani, and welcome to this presentation of United Therapeutics at the Cowen Healthcare Conference. I'm a member of the biotech research team and really appreciate you joining us today.

We have a special treat with a fireside chat discussion with the United Therapeutics management. We recently upgraded the stock, which has been around for a long time. And I think it's high time for people to pay attention. We look at the story, many under [tensions,] presumptions that people have had about some of the trends within the business have changed. And it's worth taking a look -- a closer look in the debate. I'm joined on stage here by Michael Benkowitz, who is, get your title correct, President and Chief Operating Officer.

Michael I. Benkowitz
United Therapeutics Corporation - President & COO

Got it.

Chris Shibutani
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot